Stephen Hoge - 24 May 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
24 May 2021
Net transactions value
-$3,152,070
Form type
4
Filing time
25 May 2021, 16:27:29 UTC
Previous filing
24 May 2021
Next filing
04 Jun 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $54,500 +5,000 +0.31% $10.90* 1,614,597 24 May 2021 Direct F1
transaction MRNA Common Stock Options Exercise $54,500 +5,000 +0.31% $10.90* 1,619,597 24 May 2021 Direct F1
transaction MRNA Common Stock Options Exercise $9,900 +10,000 +0.62% $0.9900* 1,629,597 24 May 2021 Direct F1
transaction MRNA Common Stock Sale $97,032 -600 -0.04% $161.72 1,628,997 24 May 2021 Direct F1, F2
transaction MRNA Common Stock Sale $1,780,297 -10,955 -0.67% $162.51 1,618,042 24 May 2021 Direct F1, F3
transaction MRNA Common Stock Sale $376,892 -2,297 -0.14% $164.08 1,615,745 24 May 2021 Direct F1, F4
transaction MRNA Common Stock Sale $706,420 -4,279 -0.26% $165.09 1,611,466 24 May 2021 Direct F1, F5
transaction MRNA Common Stock Sale $310,329 -1,869 -0.12% $166.04 1,609,597 24 May 2021 Direct F1, F6
holding MRNA Common Stock 4,116 24 May 2021 By Valhalla, LLC
holding MRNA Common Stock 151,933 24 May 2021 By Trust F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.6% $0.000000 311,972 24 May 2021 Common Stock 5,000 $10.90 Direct F1, F8
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.6% $0.000000 306,972 24 May 2021 Common Stock 5,000 $10.90 Direct F1, F8
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10,000 -2.1% $0.000000 477,431 24 May 2021 Common Stock 10,000 $0.9900 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.30 to $161.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.45 to $163.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.57 to $164.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.59 to $165.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.61 to $166.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F8 This option is fully vested and exercisable.